杰克跳投毒液免疫疗法长期有效性调查 (JAVELIN)
Jack Jumper ant (JJA) venom allergy is a uniquely Australian medical condition. It is the leading cause of venom allergy and affects up to three per cent of the population. 70 percent of people with JJA allergy will have another reaction on a repeat sting and this sensitivity appears to persist for many years.
Venom immunotherapy (VIT) has been shown to be a safe and effective treatment in the prevention of severe systemic allergic reactions (anaphylaxis) to future stings. It is currently offered to patients as standard care in Tasmania, South Australia and Victoria. However, whilst JJA VIT has been used for many years, there is a lack of evidence on the long-term benefit of the treatment and how it impacts patient quality of life.
This trial will offer patients who have completed a JJA VIT program (between 3 and < 6-years duration) and have been off-treatment for at least 18-months and < 5 years, to have a supervised JJA sting challenge and blood test to assess their JJA venom tolerance level. It will also ask them to complete a set of questionnaires at different timepoints to obtain a history of their exposure and reactions to JJA stings outside of the hospital setting (field stings), and to measure the impact of the completed VIT and knowledge of their sting challenge outcome on their quality of life and their behaviours around auto-injectors.
These measures will be used to explore the long-term effectiveness of JJA VIT and the impact of a sting challenge post VIT on a patient's quality of life.
研究概览
详细说明
This will be a prospective, multicentre, phase 4 clinical trial examining the long-term effectiveness (measured by response to an in-hospital JJA sting challenge, primary outcome) and impact on quality of life of JJA VIT involving 3 Australian tertiary hospital sites offering this treatment - Royal Hobart Hospital, Royal Adelaide Hospital and Monash Medical Centre.
Patients who have completed their JJA VIT (between 3 and <6 years duration) at one of the 3 sites and off-treatment for at least 18 months and < 5 years, will be invited to participate in the trial by their original treating site. A research team member will obtain informed e-consent and a booking for an in-clinic JJA sting challenge will be allocated. For all consented participants, quality of life (QoL), anxiety and depression scores, history of field sting reactions since treatment completion and attitudes toward adrenaline autoinjector carriage/usage will be collected via questionnaire at trial enrolment, sting challenge, 1-month post sting challenge and annually for 3-years. A blood sample will be collected immediately prior to the sting challenge at the in-clinic appointment. Participants will also be asked to consent to access retrospective data related to their completed JJA VIT course from their hospital clinical records.
Optional consents will also be sought from each participant for the collection of an extra tube of blood with the serum biobanked for future analysis, and the inclusion of their data in the National Allergy BioRepository (ALBI).
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:National Allergy Centre of Excellence
- 电话号码:61 3 99366752
- 邮箱:nace@mcri.edu.au
学习地点
-
-
South Australia
-
Adelaide、South Australia、澳大利亚、5000
- 招聘中
- Royal Adelaide Hospital
-
接触:
- National Allergy Centre of Excellence
- 电话号码:61 3 99366752
- 邮箱:nace@mcri.edu.au
-
首席研究员:
- Carlo Yuson, MD FRACP
-
-
Tasmania
-
Hobart、Tasmania、澳大利亚、7000
- 招聘中
- Royal Hobart Hospital
-
接触:
- National Allergy Centre of Excellence
- 电话号码:61 3 99366752
- 邮箱:nace@mcri.edu.au
-
首席研究员:
- Troy Wanandy, PhD
-
-
Victoria
-
Clayton、Victoria、澳大利亚、3168
- 招聘中
- Monash Medical Centre
-
接触:
- National Allergy Centre of Excellence
- 电话号码:61 3 99366752
- 邮箱:nace@mcri.edu.au
-
首席研究员:
- Kymble Spriggs, MBBS MPH FRACP FRCP FAAAAI
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Eligibility criteria
- Any adult (≥ 18 years) who has completed a JJA VIT program at one of the three participating sites.
Inclusion Criteria:
- Completed a continuous program of JJA VIT of between 3 and < 6 years duration.
- Have ceased JJA VIT for ≥ 18 months but < 5 years.
- Have the ability to provide informed consent.
Exclusion Criteria:
- Any person < 18 years.
- Any adult (≥ 18 years) who has not completed a continuous JJA VIT program of duration between 3 and < 6 years.
- Any adult (≥ 18 years) who has completed a continuous JJA VIT program of duration between 3 and < 6 years but ceased JJA VIT < 18 months or > 5 years ago.
- Any person who has a medical condition, that in the opinion of the investigator, may place them at increased risk if they were to have a sting challenge.
- Unable to understand study requirements and provide informed consent.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:完成了杰克套头衫毒液免疫疗法治疗的参与者
|
Jack Jumper Ant Venom Immunotherapy involves injections, under the skin, of gradually increasing doses of insect venom. The treatment is usually between 3-<6 years duration. Participants will have completed this treatment at least 18 months prior to their enrolment in this trial. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Presence of a systemic reaction to JJA live ant sting challenge
大体时间:Periprocedural
|
This will be assessed by the clinician and recorded as YES or NO. |
Periprocedural
|
|
Severity of a clinically assessed systemic reaction measured by The Brown Grading Criteria
大体时间:Periprocedural
|
The Brown Grading Criteria measures the severity of anaphylactic reactions by categorizing symptoms based on body systems affected and physiological impact. The tool uses a 3-point grading system: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe. Higher scores indicate more severe anaphylactic reactions. |
Periprocedural
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in presence of a systemic reaction to a field sting following cessation of Jack Jumper Ant Venom Immunotherapy as reported by the patient on a trial-specific questionnaire
大体时间:At enrolment, 1-month post procedure and annually for 3-years
|
Trial specific questionnaire to be completed by the patient which captures information about any Jack Jumper Ant stings that the patient may have had since completion of Venom Immunotherapy Treatment and whether or not they experienced any type of reaction. If no sting was experienced only one question is required to be answered. If sting/s was experienced ten questions are asked including timing, symptoms, location, treatment and environment. |
At enrolment, 1-month post procedure and annually for 3-years
|
|
Change in severity of a systemic reaction to a field sting following cessation of Jack Jumper Ant Venom Immunotherapy as measured by The Brown Grading Criteria
大体时间:At enrolment, 1-month post procedure and annually for 3-years
|
The Brown Grading Criteria measures the severity of anaphylactic reactions by categorizing symptoms based on body systems affected and physiological impact. The tool uses a 3-point grading system: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe. Higher scores indicate more severe anaphylactic reactions. |
At enrolment, 1-month post procedure and annually for 3-years
|
|
Change in attitude towards adrenaline auto-injectors as measured by the Adrenaline Auto-injector Questionnaire
大体时间:At enrolment, 1-month post procedure and annually for 3-years
|
The Adrenaline Auto-injector Questionnaire measures patient attitudes and behaviors related to adrenaline auto-injectors as a 4 question survey. Current possession of an adrenaline auto-injector (yes/no), decision-making process regarding auto-injector maintenance (doctor advice, personal decision, or other influence), carrying/storage behaviors (ranging from constant carriage to unknown location), overall attitude assessment using a 7-point scale regarding the advantages and disadvantages of carrying an auto-injector where the minimum score is 1 and the maximum score is 7. A lower score indicates a better outcome. |
At enrolment, 1-month post procedure and annually for 3-years
|
|
Change in quality of life as measured by the Vespid Quality of Life Questionnaire
大体时间:At enrolment, 1-month post procedure and annually for 3-years
|
An adapted insect allergy specific health-related quality of life questionnaire. 14 questions with 7 response options giving a score of 1-7, with lower scores representing a higher quality of life. |
At enrolment, 1-month post procedure and annually for 3-years
|
|
Change in quality of life measured using the Hospital Anxiety and Depression Scale
大体时间:At enrolment, 1-month post procedure and annually for 3-years
|
Developed to assess depression and anxiety. Each response ranges from 0 to 3, the 14 responses are added to yield a total score between 0 and 42. Higher scores indicate higher severity of anxiety and depression. |
At enrolment, 1-month post procedure and annually for 3-years
|
合作者和调查者
调查人员
- 首席研究员:Adriana Le, MBBS FRACP、Royal Hobart Hospital
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
After the data has been cleaned and database has been locked, the de-identified data and if consented, personal identifying information, will be shared to National Allergy Centre of Excellence (NACE) Allergy BioRepository via a safe and secure mechanism, for storage and use in future allergy research.
IPD 共享时间框架
At 6 months post the commencement of JAVELIN, de-identified data, encrypted with NACE unique identifier codes and secure linkage key tokens, will be transferred to the ALBI platform, for storage, integration and sharing for future HREC-approved allergy research purposes. Data once in ALBI remains indefinitely.
IPD 共享访问标准
ALBI will only provide researchers with non-identifiable information following the Scientific Access Framework. Researchers need to apply for access to ALBI data. Once approved, data will be made available to the researchers by logging in through a secure research platform. Researchers will not have access to the entire ALBI system as they will be provided extracts from ALBI of non-identifiable information related to their specific request and approval. Information will only be shared with ethically approved future allergy research studies.
IPD 共享支持信息类型
- 研究方案
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.